Sign in to Administration. The default account is administrator with blank password.
Home News Latest News HPRA Drug Safety Newsletter Edition 92

HPRA Drug Safety Newsletter Edition 92

Home News Latest News HPRA Drug Safety Newsletter Edition 92
April 30, 2019

The 92nd edition of the HPRA Drug Safety Newsletter.


 

The 92nd edition of the HPRA Drug Safety Newsletter includes information on the following medicines:

  • Use of Lemtrada (alemtuzumab) restricted while European Medicines Agency (EMA) review is ongoing

  • SGLT-2 inhibitors and risk of Fournier’s Gangrene (necrotising fasciitis of the perineum)

  • Cobicistat boosted darunavir and elvitegravir: avoid use in pregnancy due to potential risk of virological failure in the second and third trimester

  • Direct-Acting Antivirals for Chronic Hepatitis C – Risk of Hypoglycaemia in Patients with Diabetes

  • Biotin – Interference with clinical laboratory tests

  • Adverse Reaction Reporting

The online versions of the DSN contains hyperlinks to product information and other documents on the HPRA and European Medicines Agency (EMA) websites, as appropriate.

Subscribe to our eZine

Receive our monthly newsletter with news and other content relevant to the Irish nursing and midwifery professions.